The main purpose is to determine whether Triferic, administered orally with Shohl's solution, is safe and effective for the treatment of iron-refractory iron-deficiency anemia (IRIDA).

Start Date17 Jan 2017

Sponsor / Collaborator

Rockwell Medical, Inc.

100 Clinical Results associated with Ferrocholinate

100 Translational Medicine associated with Ferrocholinate

100 Patents (Medical) associated with Ferrocholinate

Literatures (Medical) associated with Ferrocholinate

01 Jun 2013·Materials Letters

A novel route in the synthesis of magnetite nanoparticles

Author: Ivana Opačak ; Svetozar Musić ; Hideki Hashimoto ; Mira Ristić ; Tatsuo Fujii

A novel route in the preparation of magnetite nanoparticles is reported.This is based on autoclaving of iron choline citrate dissolved in mixed water/ethanol or water solution and neutralized with NH₄OH solutionThe magnetite precipitates were characterized by XRD, Moessbauer, FT-IR, HRTEM, and magnetometric measurements.All the precipitated magnetite particles were in the nanosize range as shown by HRTEM.They did not contain organic residues or any other iron (hydrous) oxide phase.

01 May 2013·Journal of Alloys and Compounds

The synthesis and microstructure of goethite particles precipitated in highly alkaline media

Author: Ivana Opačak ; Mira Ristić ; Svetozar Musić

Iron choline citrate was used as the starting chem. in the synthesis of long goethite rods in highly alk. media.Goethite particles were characterized by ⁵⁷Fe Mossbauer, XRD, FT-IR, UV/Vis/NIR and FE-SEM.The phase composition and morphol. of goethite particles did not change for up to 14 days of heating their suspension at 90 °C.However, upon autoclaving the suspension at 160 °C, the phase transformation goethite → hematite occurred through the dissolution/recrystallization mechanism, as confirmed by FE-SEM.Upon heating the goethite particles in air at 300 °C for 2-4 h hematite was formed with a preserved morphol. of the original goethite particles.The hematite particles formed at 800 °C showed a changes in morphol. due to the common effect of the solid-state rearrangement involving a loss of residual OH groups and sintering.

01 Aug 2011·European Journal of Medicinal ChemistryQ1 · MEDICINE

Ligand-based discovery of novel trypanosomicidal drug-like compounds: In silico identification and experimental support

Q1 · MEDICINE

Article

Author: Alina Montero ; Vicente J. Arán ; Yovani Marrero-Ponce ; Facundo Pérez-Giménez ; Alicia Gómez-Barrio ; Alfredo Alvarez Bello ; Miriam Rolón ; Francisco Torrens ; Concepción Abad ; Juan Alberto Castillo-Garit ; José A. Escario ; Maria Celeste Vega

Two-dimensional bond-based linear indices and linear discriminant analysis are used in this report to perform a quantitative structure-activity relationship study to identify new trypanosomicidal compounds. A database with 143 anti-trypanosomal and 297 compounds having other clinical uses, are utilized to develop the theoretical models. The best discriminant models computed using bond-based linear indices provides accuracies greater than 90 for both training and test sets. Our models identify as anti-trypanosomals five out of nine compounds of a set of already-synthesized substances. The in vitro anti-trypanosomal activity of this set against epimastigote forms of Trypanosoma cruzi is assayed. Both models show a perfect agreement between theoretical predictions and experimental results. The compounds identified as active ones show more than 98% of anti-epimastigote elimination (AE) at a concentration of 100 μg/mL. Besides, three compounds show more than 70% of AE at a concentration of 10 μg/mL. Finally, compounds with the best "activity against epimastigote forms/unspecific cytotoxicity" ratio are evaluated using an amastigote susceptibility assay. It should be noticed that, compound Va7-71 exhibit a 100% of intracellular amastigote elimination and shows similar activity when compared to a standard trypanosomicidal as nifurtimox. Finally, we can emphasize that, the present algorithm constitutes a step forward in the search for efficient ways of discovering new anti-trypanosomal compounds.

100 Deals associated with Ferrocholinate

External Link

KEGG	Wiki	ATC	Drug Bank
D07956	-	B03AA01	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Iron-Deficiency	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis